查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1673817

製藥和生物技術臨床階段合作條款和協議（2020-2025年）

Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2020-2025
出版日期: | 出版商: Current Partnering | 英文 1500+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告研究了製藥和生物技術行業的臨床階段合作條款和協議，並提供了全面的資料驅動分析，說明公司如何以及為何簽訂臨床階段合作協議，以及這些協議所依據的財務和戰略條款。本報告還提供了有關製藥和生物技術行業臨床階段藥物開發合作的交易結構、談判動態和財務考慮的無與倫比的見解。

在臨床階段，授權協議通常授予被授權人開發授權人產品或技術的獨家權利或選擇權，通常涵蓋第一階段、第二階段和第三階段試驗。此類協議通常包含多項內容，包括共同研發、共同開發和商業化策略。

本報告提供了醫療保健領域當前臨床階段交易的詳細資訊，可以幫助公司評估市場趨勢，最佳化談判策略和基準交易結構。

本報告提供：

  • 2020年及以後生物製藥產業臨床階段交易趨勢分析
  • 詳細的合約結構，包括總金額、里程碑、特許權使用費等。
  • 實際臨床階段合約案例研究
  • 可查閱超過 1,670 例臨床階段病例（如有合約記錄，另行提供）
  • 2020年及以後最活躍的臨床階段交易者的合作夥伴簡介
  • 對最高價值臨床階段交易進行詳細分析

目錄

執行摘要

第1章 簡介

第2章 為什麼各公司要在臨床階段化合物上合作？

  • 臨床階段聯盟的作用
    • 臨床階段的許可
    • 臨床階段許可
  • 第一階段、第二階段與第三階段交易的差異
  • 為什麼要簽訂臨床階段合作協議？
    • 授權方為何參與臨床階段交易
    • 為什麼被授權者要達成臨床階段交易
  • 臨床階段合作協議的未來

第3章 臨床階段交易策略與結構

  • 公司在什麼階段進行合作？
    • 製藥/生技領域的早期合作
    • 製藥/生技聯盟
  • 早期與晚期夥伴關係：風險與成本
  • 各公司在臨床階段合作上花了多少錢？
  • 純合作協議與多部分合作協議
  • 純許可協議的結構
    • 純許可協議範例
    • 個案研究
  • 多部分臨床階段合作協議
    • 多部分臨床階段條款範例
    • 個案研究

第4章 臨床階段合作夥伴付款策略

  • 臨床階段付款策略
  • 付款方式
    • 標題
    • 預付
    • 貸款
    • 可轉換貸款
    • 公平
    • 研發資金
    • 許可證費用
    • 里程碑
    • 版稅
    • 現金
    • 選擇

第5章 臨床階段交易趨勢

  • 長期臨床階段合作
    • 2020年及以後第一階段的交易趨勢
    • 2020年以後的第二階段交易趨勢
    • 2020年以後的第三階段交易趨勢
  • 依交易類型劃分的臨床階段夥伴關係
  • 依疾病類型劃分的臨床階段合作
  • 依技術類型劃分的臨床階段合作夥伴關係
  • 2020年以來最活躍的企業臨床階段合作夥伴關係

第6章 臨床階段合作付款條款

  • 臨床付款條款指南
    • 預付
    • 里程碑
    • 版稅
  • 臨床階段付款條款：交易資料分析
    • 公開資料
    • 調查資料
  • 付款條件分析
    • 臨床階段合作的頭條付款
    • 臨床階段交易的預付款
    • 臨床階段交易的里程碑付款
    • 臨床階段專利使用費率
  • 臨床階段財務中位數
    • 臨床階段主要資料
    • 臨床階段預付款金額
    • 臨床里程碑金額
    • 臨床階段特許權使用費金額

第7章 關鍵臨床階段交易

  • 依價值排名的頂級臨床階段交易

第8章 25 大臨床階段交易者

  • 25 大最活躍的臨床階段交易者

第9章 臨床階段合作協議目錄

  • 自2020年起的臨床階段商業協議

第10章 臨床階段交易（依開發階段劃分）

  • 依臨床階段劃分的交易
  • 第一階段
  • 第二階段
  • 第三階段
  • 申請階段

附錄

關於 Wildwood Ventures

簡介目錄
Product Code: CP2058

Clinical Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025)

The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2020-2025 report provides a comprehensive, data-driven analysis of how and why companies engage in clinical-stage partnering agreements, as well as the financial and strategic terms shaping these collaborations. This essential industry resource delivers unparalleled insights into deal structures, negotiation dynamics, and financial considerations for clinical-stage drug development partnerships.

At the clinical stage, licensing agreements typically grant the licensee exclusive rights or options to develop a licensor's product or technology, often covering Phase I, Phase II, and Phase III trials. These agreements are frequently multi-component, involving collaborative R&D, co-development, and commercialization strategies.

This report provides detailed intelligence on the latest clinical-stage agreements in the healthcare sector, helping companies evaluate market trends, optimize negotiation strategies, and benchmark deal structures.

A Must-Have Resource for Biotech and Pharma Dealmakers

The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025) report is an indispensable resource for business development, legal, and financial professionals involved in biopharma dealmaking.

With comprehensive insights, a vast deal database, and direct access to contract documents, this report serves as the ultimate tool for:

  • Benchmarking deal structures and financial terms
  • Optimizing negotiation strategies
  • Assessing potential partners' flexibility
  • Identifying trends in clinical-stage partnerships
  • Why This Report is Essential for Dealmakers
  • Understanding the flexibility and negotiation strategies of potential partners is critical when structuring clinical-stage partnerships. While headline financial terms (e.g., upfront payments, milestones, royalties) provide a broad overview, contract documents reveal the actual triggers and conditions for these payments-details often missing from press releases and traditional deal databases.
  • This report provides a comprehensive listing of over 1,670 clinical-stage deals announced since 2020, including financial terms where available. Additionally, it features direct links to online deal records, along with publicly available contract documents submitted to the SEC.
  • By analyzing these agreements, companies can gain critical insights to refine deal strategies, assess partner flexibility, and structure competitive agreements.
  • Comprehensive Analysis of Clinical-Stage Partnering Trends

The first chapters of this report offer a detailed orientation to clinical-stage deal-making, including:

Chapter 1 - Introduction to the report

Chapter 2 - Why companies engage in clinical-stage partnerships

Chapter 3 - Strategic approaches and deal structures, with case studies

Chapter 4 - Payment strategies, including upfronts, milestones, and royalties

Chapter 5 - Analysis of clinical-stage deal activity (2020-2025), categorized by year, stage of development, therapeutic area, technology type, and key dealmakers

Chapter 6 - In-depth financial analysis of headline values, upfront payments, milestone triggers, and royalty rates for Phase I, Phase II, and Phase III deals

Chapter 7 - A review of the leading clinical-stage deals by headline value

Chapter 8 - Profiles of the top 25 most active clinical-stage dealmakers

Chapter 9 - A database of clinical-stage partnering agreements, including contract documents where available

Chapter 10 - A comprehensive directory of all clinical-stage deals announced since 2020, categorized by Phase I, Phase II, and Phase III

  • Key Benefits of the Report

This must-have industry resource provides exclusive insights to help companies assess, structure, and negotiate their own clinical-stage partnerships. Key benefits include:

  • Unparalleled Market Insights - Gain a deep understanding of clinical-stage deal trends shaping the pharma and biotech industry since 2020.
  • Exclusive Financial Data Access - Unlock headline values, upfront payments, milestone structures, and royalty terms, giving you a competitive edge in deal negotiations.
  • Comprehensive Deal Database - Access a curated repository of over 1,670 clinical-stage agreements, including contract documents where available, for unmatched transparency and benchmarking.
  • Deep-Dive into Industry Leaders - Analyze actual clinical-stage deals entered into by the top 25 global pharma and biotech companies, alongside emerging biopharma players.
  • Proven Case Studies & Structural Analysis - Examine real-world deal structures and case studies to refine your own partnering and negotiation strategies.
  • High-Value Deal Identification - Pinpoint the most lucrative clinical-stage deals signed since 2020, gaining insight into premium industry transactions.
  • Profile the Most Active Dealmakers - Identify the key players driving clinical-stage collaborations, ensuring you target the right partners.
  • Strategic Deal Mapping - Navigate a full A-Z listing of clinical-stage agreements, categorized by company, development phase, deal type, therapeutic area, and technology focus.
  • Negotiate with Confidence - Understand the key terms and conditions top-tier companies have agreed to in previous deals, helping you structure optimal agreements.
  • Robust Due Diligence Support - Conduct data-backed assessments to determine the viability and competitiveness of your proposed deal terms with potential partners.
  • Report Scope

The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025) report provides:

  • Trends in clinical-stage dealmaking in the biopharma industry since 2020
  • Detailed deal structures, including upfront, milestone, and royalty terms
  • Case studies of real-life clinical-stage agreements
  • Access to over 1,670 clinical-stage deals, with contract records where available
  • Partnering profiles of the most active clinical-stage dealmakers since 2020
  • Analysis of the highest-value clinical-stage deals

Each deal record is indexed by:

  • Company (A-Z)
  • Headline Value
  • Stage of Development at Signing (Phase I, Phase II, Phase III)
  • Deal Type
  • Specific Therapy Focus
  • Critical Questions Answered

By analyzing actual contract agreements, this report provides definitive answers to critical questions such as:

  • What specific rights are granted in each agreement?
  • What exclusivity terms apply?
  • How is the deal structured financially? (Upfronts, milestones, royalties)
  • Who controls development, manufacturing, and commercialization?
  • How are intellectual property rights handled?
  • What are the termination conditions for the agreement?
  • What dispute resolution mechanisms are in place?
  • How are confidentiality and publication rights managed?
  • Gain the competitive edge-explore the report today.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Why do companies partner clinical stage compounds?

  • 2.1. Introduction
  • 2.2. The role of clinical stage partnering
    • 2.2.1. In-licensing at clinical stage
    • 2.2.2. Out-licensing at clinical stage
  • 2.3. Difference between phase I, II and III stage deals
  • 2.4. Reasons for entering into clinical stage partnering deals
    • 2.4.1. Licensors reasons for entering clinical stage deals
    • 2.4.2. Licensees reasons for entering clinical stage deals
  • 2.5. The future of clinical stage partnering deals

Chapter 3 - Clinical stage deal strategies and structure

  • 3.1. Introduction
  • 3.2. At what stage do companies partner?
    • 3.2.1. Partnering early in pharmaceutical/biotech
    • 3.2.1.1. Discovery and preclinical stage partnering case studies
    • 3.2.1.1.a. Case study 1
    • 3.2.1.1.b. Case study 2
    • 3.2.1.1.c. Case study 3
    • 3.2.1.1.d. Case study 4
    • 3.2.2. Partnering later in pharmaceutical/biotech
    • 3.2.2.1. Clinical stage partnering case studies
    • 3.2.2.1.a. Case study 5
    • 3.2.2.1.b. Case study 6
    • 3.2.2.1.c. Case study 7
    • 3.2.2.1.d. Case study 8
  • 3.3. Early and later stage partnering - a risk/cost comparison
  • 3.4. What do companies spend on clinical stage partnering?
  • 3.5. Pure versus multi-component partnering deals
  • 3.6. Pure licensing agreement structure
    • 3.6.1. Example pure licensing agreements
    • 3.6.1.a. Case study 9
    • 3.6.1.b. Case study 10
  • 3.7. Multicomponent clinical stage partnering agreements
    • 3.7.1. Example multicomponent clinical stage clauses
    • 3.7.1.a. Case study 11

Chapter 4 - Clinical stage partnering payment strategies

  • 4.1. Introduction
  • 4.2. Clinical stage payment strategies
  • 4.3. Payment options
    • 4.3.1. Headline values
    • 4.3.2. Upfront payments
    • 4.3.2.1. Conditionality of upfront payments
    • 4.3.3. Loans
    • 4.3.4. Convertible loans
    • 4.3.5. Equity
    • 4.3.6. R&D funding
    • 4.3.7. Licensing fees
    • 4.3.8. Milestone payments
    • 4.3.9. Royalty payments
    • 4.3.9.1. Issues affecting royalty rates
    • 4.3.9.2. Royalties on combination products
    • 4.3.9.2.a. Case study 12
    • 4.3.9.3. Guaranteed minimum/maximum annual payments
    • 4.3.9.4. Royalty stacking
    • 4.3.9.5. Royalties and supply/purchase contracts
    • 4.3.10. Quids
    • 4.3.11. Option payments

Chapter 5 - Trends in clinical stage deal making

  • 5.1. Introduction
  • 5.2. Clinical stage partnering over the years
    • 5.2.1. Trends in phase I deals since 2020
    • 5.2.1.1. Attributes of phase I deals
    • 5.2.2. Trends in phase II deals since 2020
    • 5.2.2.2. Attributes of phase II deals
    • 5.2.3. Trends in phase III deals since 2020
    • 5.2.3.1. Attributes of phase III deals
  • 5.3. Clinical stage partnering by deal type
  • 5.4. Clinical stage partnering by disease type
  • 5.5. Partnering by clinical stage technology type
  • 5.6. Clinical stage partnering by most active company since 2020

Chapter 6 - Payment terms for clinical stage partnering

  • 6.1. Introduction
  • 6.2. Guidelines for clinical stage payment terms
    • 6.2.1. Upfront payments
    • 6.2.2. Milestone payments
    • 6.2.3. Royalty payments
  • 6.3. Clinical stage payment terms - deal data analysis
    • 6.3.1. Public data
    • 6.3.2. Survey data
  • 6.4. Payment terms analysis
    • 6.4.1. Clinical stage partnering headline values
    • 6.4.2. Clinical stage deal upfront payments
    • 6.4.3. Clinical stage deal milestone payments
    • 6.4.4. Clinical stage royalty rates
  • 6.5 Clinical stage median financials
    • 6.5.1. Clinical stage headline value
    • 6.5.2. Clinical stage upfront value
    • 6.5.3. Clinical stage milestone value
    • 6.5.4. Clinical stage royalty value

Chapter 7 - Leading clinical stage deals

  • 7.1. Introduction
  • 7.2. Top clinical stage deals by value

Chapter 8 - Top 25 most active clinical stage dealmakers

  • 8.1. Introduction
  • 8.2. Top 25 most active clinical stage dealmakers

Chapter 9 - Clinical stage partnering contracts directory

  • 9.1. Introduction
  • 9.2. Clinical stage deals with contracts since 2020

Chapter 10 - Clinical stage deal making by development stage

  • 10.1. Introduction
  • 10.2. Deals by clinical stage
  • Phase I
  • Phase II
  • Phase III
  • Regulatory

Appendices

  • Appendix 1 - Clinical stage dealmaking by companies A-Z
  • Appendix 2 - Clinical stage dealmaking by industry sector
  • Appendix 3 - Clinical stage dealmaking by stage of development
  • Appendix 4 - Clinical stage dealmaking by therapy area
  • Appendix 5 - Clinical stage dealmaking by technology type

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Definition of clinical phases in dealmaking
  • Figure 2: Components of the pure licensing deal structure
  • Figure 3: Payment options for clinical stage partnering deals
  • Figure 4: Issues affecting royalty rates
  • Figure 5: Clinical stage partnering by deal type since 2020
  • Figure 6: Clinical stage partnering by disease type since 2020
  • Figure 7: Clinical stage partnering by technology type since 2020
  • Figure 8: Top 25 most active clinical stage dealmakers, 2020 - 2025
  • Figure 9: Review of upfront payments for clinical stage deals
  • Figure 10: Review of milestone payments for clinical stage deals
  • Figure 11: Review of royalty payments for clinical stage deals
  • Figure 12: Clinical stage deals with a headline value
  • Figure 13: Clinical stage deals with an upfront value
  • Figure 14: Clinical stage deals with a milestone value
  • Figure 15: Clinical stage deals with a royalty rate value
  • Figure 16: Top clinical stage deals by value since 2020
  • Figure 17: Most active clinical stage dealmakers 2020 - 2025